SynthesisOtolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery2026
The Global Burden of Cholesteatoma: A Systematic Review and Meta-analysis.
Synthesis in Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Primary Intracranial Cholesteatoma Presenting as a Cerebellar Mass Without Otologic Symptoms.Cureus · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
22 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThis systematic review and meta-analysis sought to estimate the global and World Health Organization (WHO) regional prevalence and burden of cholesteatoma. DATA SOURCES: PubMed, APA PsycINFO, the Cochrane Library, Embase, and WHO International Clinical Trials Registry Platform (ICTRP) from 2010 to 2025. REVIEW
methodsTeams of independent reviewers assessed each study for inclusion. Studies reporting primary data on cholesteatoma prevalence, recurrence, or its impact were included. The primary outcome was the global prevalence, whereas secondary outcomes were regional prevalence and recidivism rates, treatment, and complications. A random-effects meta-analysis was used to pool data, and study quality and publication bias were assessed. This study was registered with PROSPERO (CRD42024533132).
resultsForty-six eligible studies were included in the meta-analysis. The pooled global prevalence of cholesteatoma was estimated at 4.02 per 1000 persons (95% CI 1.79-7.10). By the WHO regions, the pooled prevalence of cholesteatoma in the Western Pacific Region, European Region, South East Asian Region, Region of the Americas, and African Region was estimated at 5.73 per 1000 persons (95% CI 1.00-13.87), 2.32 per 1000 persons (95% CI 2.23-2.42), 3.30 per 1000 persons (95% CI 2.65-4.11), 0.06 per 1000 persons (95% CI 0.00-0.00), and 7.32 per 1000 persons (95% CI 2.77-13.96), respectively. The prevalence of hearing loss in cholesteatoma was estimated at 75.68 per 100 cases (95% CI 59.02-89.24).
conclusionThis meta-analysis is the first to systematically quantify global and regional cholesteatoma prevalence, complications, and treatment approaches, highlighting regional disparities and informing public health strategies and policy globally.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.